4Schwartz TF,Spaczynski M,Schneider A,et al.Immunogenicityand tolerability of an HPV-16/18 AS04-adjuvanted prophylacticcervicalcancer vaccine in women aged 15-55years[J].Vaccine,2009,27(4):581-587. 被引量：1
5Hildesheim A,Herrero R,Wacholder S,et al.Effect of humanpapillomavirus 16/18 L1 viruslike particle vaccine among youngwomen with preexisting infection;a randomized trial[J].JAMA,2007,298(7):743-753. 被引量：1
5Anttila A, Pukkala E, Soderman B, et al. Effect of organized screening on cervical cancer incidence and mortality in Finland,1963-1995:Recent increase in cervical cancer incidence [J]. Int J Cancer, 1999, 83(1):59～65 被引量：1
6Brewster WR, DiSaia PJ, Monk BJ, et al. Young age as a prognostic factor in cervical cancer: results of a population-based study[I]. AmJ Obstet Gynecol, 1999, 180(6 Pt1):1464-1467 被引量：1
7Crowther ME. Is the nature of cervical cardnoma changing in young women[J]. Obstetrical & Gynecological Survey, 1995, 50(1):71 -82 被引量：1
8Marielle AEN, Jan MMW, Theo JMH, et al. Relation of human popillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study [J].Lancet, 1999, 354(9172):20-25 被引量：1
